Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Biologicals
Femme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscularly according to a 0, 1, 6-month schedule in females aged 18-25 years
To evaluate whether there is an increased incidence of neuroinflammatory AIDs or other autoimmune diseases, with onset during the theoretical risk period of 12 months (the period beginning with admini...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi-Pasteur-MSDs DTPa-IPV (Tetravac), when co-administered with MMRV (Priorix Tetra) in 5 to 6-year-old healthy children
To demonstrate that GSK Biologicals dTpa-IPV vaccine is non-inferior to Sanofi-Pasteur-MSDs DTPa-IPV vaccine, in terms of seroprotection rates against diphtheria, tetanus and poliovirus types 1, 2 a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’ rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa
To assess the safety and reactogenicity of 3 doses of GSK Biologicals’ HRV vaccine versus placebo in HIV infected infants.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Biologicals combined hepatitis A / hepatitis B vaccine administered according to a 0, 6 month schedule versus Twinrix™ Junior administered according to a 0, 1, 6 month schedule in healthy children between 1 to 11 years old
For the primary study: To demonstrate that the combined hepatitis A / hepatitis B (720/20) vaccine is not more reactogenic than Twinrix™ Junior. For the long term follow up (LTFU): To evaluate a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years
• To evaluate 1 month after the third dose (i.e. at Month 7), the immune responses to the candidate HPV-16/18 vaccine (as determined by anti-HPV-16/18 ELISA) in healthy male subjects aged 10-18 years ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase IIb, controlled, randomised, multicenter, single blind study to demonstrate the Non-Inferiority of the low dose influenza vaccine with or without adjuvant AS03 compared with Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in elderly 60 years of age and older
To demonstrate the immunological non-inferiority (GMT) of the low dose adjuvanted (AS03) influenza vaccine versus Fluarix given intramuscularly in elderly (aged >60 years), 21 days following vaccinati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase III, open, randomized, controlled study to demonstrate the immunogenicity, reactogenicity and safety of GSK Biologicals meningococcal serogroup ACWY conjugate vaccine (GSK134612, MenACWY-TT) co-administered with Infanrix hexa compared to individual administration of each vaccine, in healthy 12- through 23-month-old children
Co-administration of MenACWY-TT and Infanrix hexa In subjects of the MenACWY-TT + Infanrix hexa and MenACWY-TT groups: To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine co-adminis...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A study to evaluate the safety and immunogenicity of a candidate Ebola Vaccine in children
To assess the safety and reactogenicity of a single IM dose of the ChAd3 EBO-Z vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Safety and immunogenicity of a candidate tuberculosis (TB) vaccine in adults with TB disease
To assess the safety and reactogenicity of GSK Biologicals’ candidate TB vaccine M72/AS01E in the study population.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase II, double-blind study to evaluate the safety, reactogenicity and immunogenicity of two different formulations of GSK Biologicals’ pneumococcal protein candidate vaccine, when given as a booster dose in healthy young adults previously vaccinated in the primary vaccination study SPNG-001 (111651)
•To assess the safety and reactogenicity of a booster dose of two formulations of GSK Biologicals’ candidate pneumococcal proteins vaccine when administered intramuscularly in healthy adults, in terms...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
11
12
13
14
15
16
17
18
19
20
Suivant